search
Back to results

BI 671800 ED in Steroid-naive Asthmatic Patients

Primary Purpose

Asthma

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
BI 671800
Fluticasone propionate placebo
Fluticasone propionate
BI 671800 Placebo
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  1. Signed informed consent consistent with ICH-GCP
  2. Three month history of reversible (12% with 200 mL) asthma (according to GINA) with following spirometry at randomization: FEV1 60%-85%.
  3. No ICS previous 3 months prior to screening.
  4. Diagnosis of asthma prior to 40 years.
  5. ACQ at least 1.5 at randomization.
  6. Male or female, 18 to 65 years.
  7. Non-smokers or ex-smokers ( less than 10 pack year history) with negative cotinine screen.
  8. Able to perform PFT

Exclusion criteria:

  1. Significant diseases other than asthma or allergic rhinitis.
  2. Hepatic transaminases or total bilirubin greater than 1.5 ULN.
  3. Hospitalizations for asthma or asthma related intubation within 3 months.
  4. Uncontrolled asthma.
  5. Respiratory tract infection or exacerbation within 4 weeks.
  6. FEV1 less than 40%, more than 12 puffs of SABA on more than two consecutive days or asthma exacerbation during the run-in period.
  7. Participation in another interventional study.
  8. Pregnant or nursing women.
  9. Women of child bearing potential nor using appropriate methods of birth control as defined by protocol

Sites / Locations

  • 1268.17.01043 Boehringer Ingelheim Investigational Site
  • 1268.17.01009 Boehringer Ingelheim Investigational Site
  • 1268.17.01006 Boehringer Ingelheim Investigational Site
  • 1268.17.01040 Boehringer Ingelheim Investigational Site
  • 1268.17.01024 Boehringer Ingelheim Investigational Site
  • 1268.17.01003 Boehringer Ingelheim Investigational Site
  • 1268.17.01015 Boehringer Ingelheim Investigational Site
  • 1268.17.01001 Boehringer Ingelheim Investigational Site
  • 1268.17.01016 Boehringer Ingelheim Investigational Site
  • 1268.17.01033 Boehringer Ingelheim Investigational Site
  • 1268.17.01045 Boehringer Ingelheim Investigational Site
  • 1268.17.01036 Boehringer Ingelheim Investigational Site
  • 1268.17.01025 Boehringer Ingelheim Investigational Site
  • 1268.17.01005 Boehringer Ingelheim Investigational Site
  • 1268.17.01034 Boehringer Ingelheim Investigational Site
  • 1268.17.01014 Boehringer Ingelheim Investigational Site
  • 1268.17.01030 Boehringer Ingelheim Investigational Site
  • 1268.17.01027 Boehringer Ingelheim Investigational Site
  • 1268.17.01032 Boehringer Ingelheim Investigational Site
  • 1268.17.01010 Boehringer Ingelheim Investigational Site
  • 1268.17.01037 Boehringer Ingelheim Investigational Site
  • 1268.17.01022 Boehringer Ingelheim Investigational Site
  • 1268.17.01008 Boehringer Ingelheim Investigational Site
  • 1268.17.01011 Boehringer Ingelheim Investigational Site
  • 1268.17.01004 Boehringer Ingelheim Investigational Site
  • 1268.17.01038 Boehringer Ingelheim Investigational Site
  • 1268.17.01042 Boehringer Ingelheim Investigational Site
  • 1268.17.01007 Boehringer Ingelheim Investigational Site
  • 1268.17.01031 Boehringer Ingelheim Investigational Site
  • 1268.17.01039 Boehringer Ingelheim Investigational Site
  • 1268.17.01026 Boehringer Ingelheim Investigational Site
  • 1268.17.01029 Boehringer Ingelheim Investigational Site
  • 1268.17.01049 Boehringer Ingelheim Investigational Site
  • 1268.17.01019 Boehringer Ingelheim Investigational Site
  • 1268.17.01012 Boehringer Ingelheim Investigational Site
  • 1268.17.01023 Boehringer Ingelheim Investigational Site
  • 1268.17.01048 Boehringer Ingelheim Investigational Site
  • 1268.17.01028 Boehringer Ingelheim Investigational Site
  • 1268.17.01035 Boehringer Ingelheim Investigational Site
  • 1268.17.01047 Boehringer Ingelheim Investigational Site
  • 1268.17.61001 Boehringer Ingelheim Investigational Site
  • 1268.17.02012 Boehringer Ingelheim Investigational Site
  • 1268.17.02010 Boehringer Ingelheim Investigational Site
  • 1268.17.02014 Boehringer Ingelheim Investigational Site
  • 1268.17.02015 Boehringer Ingelheim Investigational Site
  • 1268.17.02003 Boehringer Ingelheim Investigational Site
  • 1268.17.02013 Boehringer Ingelheim Investigational Site
  • 1268.17.02001 Boehringer Ingelheim Investigational Site
  • 1268.17.02004 Boehringer Ingelheim Investigational Site
  • 1268.17.57003 Boehringer Ingelheim Investigational Site
  • 1268.17.57004 Boehringer Ingelheim Investigational Site
  • 1268.17.57002 Boehringer Ingelheim Investigational Site
  • 1268.17.82007 Boehringer Ingelheim Investigational Site
  • 1268.17.82001 Boehringer Ingelheim Investigational Site
  • 1268.17.82002 Boehringer Ingelheim Investigational Site
  • 1268.17.82004 Boehringer Ingelheim Investigational Site
  • 1268.17.82005 Boehringer Ingelheim Investigational Site
  • 1268.17.82006 Boehringer Ingelheim Investigational Site
  • 1268.17.82003 Boehringer Ingelheim Investigational Site
  • 1268.17.82008 Boehringer Ingelheim Investigational Site
  • 1268.17.52002 Boehringer Ingelheim Investigational Site
  • 1268.17.52001 Boehringer Ingelheim Investigational Site
  • 1268.17.52004 Boehringer Ingelheim Investigational Site
  • 1268.17.52003 Boehringer Ingelheim Investigational Site
  • 1268.17.64001 Boehringer Ingelheim Investigational Site
  • 1268.17.64003 Boehringer Ingelheim Investigational Site
  • 1268.17.64002 Boehringer Ingelheim Investigational Site
  • 1268.17.51003 Boehringer Ingelheim Investigational Site
  • 1268.17.51002 Boehringer Ingelheim Investigational Site
  • 1268.17.51006 Boehringer Ingelheim Investigational Site
  • 1268.17.51004 Boehringer Ingelheim Investigational Site
  • 1268.17.51005 Boehringer Ingelheim Investigational Site
  • 1268.17.51001 Boehringer Ingelheim Investigational Site
  • 1268.17.63007 Boehringer Ingelheim Investigational Site
  • 1268.17.63002 Boehringer Ingelheim Investigational Site
  • 1268.17.63001 Boehringer Ingelheim Investigational Site
  • 1268.17.63003 Boehringer Ingelheim Investigational Site
  • 1268.17.63004 Boehringer Ingelheim Investigational Site
  • 1268.17.63005 Boehringer Ingelheim Investigational Site
  • 1268.17.63006 Boehringer Ingelheim Investigational Site
  • 1268.17.86210 Boehringer Ingelheim Investigational Site
  • 1268.17.86211 Boehringer Ingelheim Investigational Site
  • 1268.17.86207 Boehringer Ingelheim Investigational Site
  • 1268.17.86208 Boehringer Ingelheim Investigational Site
  • 1268.17.86209 Boehringer Ingelheim Investigational Site
  • 1268.17.86201 Boehringer Ingelheim Investigational Site
  • 1268.17.86202 Boehringer Ingelheim Investigational Site
  • 1268.17.86203 Boehringer Ingelheim Investigational Site
  • 1268.17.86204 Boehringer Ingelheim Investigational Site
  • 1268.17.86205 Boehringer Ingelheim Investigational Site
  • 1268.17.86206 Boehringer Ingelheim Investigational Site
  • 1268.17.86200 Boehringer Ingelheim Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Active Comparator

Placebo Comparator

Experimental

Experimental

Arm Label

BI 671800 (low dose)

Fluticasone propionate

Placebo

BI 671800 (medium dose)

BI 671800 (high dose)

Arm Description

Patients receive BI 671800 (low dose) capsules twice daily

Patients inhale from Fluticasone propionate metered dose inhaler (MDI) twice daily

Patients receive placebo capsules twice daily

Patients receive BI 671800 (medium dose) capsules twice daily

Patients receive BI 671800 (high dose) capsules twice daily

Outcomes

Primary Outcome Measures

Forced Expiratory Volume in One Second (FEV1) % Predicted Trough Change From Baseline (Mean Observed in the 2 Weeks Prior to Treatment) After Six Weeks of Treatment
Forced expiratory volume in one second (FEV1) % predicted trough change from baseline (mean observed in the 2 weeks prior to treatment) after 6 weeks of treatment, where trough FEV1 % predicted was defined as the mean of the FEV1 % predicted trough values at 25 minutes and 10 minutes prior to dosing on clinic visit. MMRM in the statistical test comments is mixed effects model with repeated measures.

Secondary Outcome Measures

Asthma Control Questionnaire (ACQ) Mean Score Change From Baseline After Six Weeks of Treatment
Asthma Control Questionnaire (ACQ) mean score change from baseline (mean ACQ score obtained at Week 0) after six weeks of treatment. The Asthma Control Questionnaire (ACQ) is a patient-reported outcome questionnaire containing 7 items. The items are equally weighted and the ACQ score is the mean of the 7 items and therefore between 0 (well controlled) and 6 (extremely poorly controlled) These questions based on recall of the previous 7 days comprise breathlessness, nocturnal waking, symptoms on waking, activity limitation, wheeze, frequency of short-acting beta-adrenergic (SABA) use, and categorized pre-bronchodilator FEV1% predicted.

Full Information

First Posted
March 19, 2010
Last Updated
May 27, 2022
Sponsor
Boehringer Ingelheim
search

1. Study Identification

Unique Protocol Identification Number
NCT01092143
Brief Title
BI 671800 ED in Steroid-naive Asthmatic Patients
Official Title
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Completed
Study Start Date
March 18, 2010 (Actual)
Primary Completion Date
March 26, 2011 (Actual)
Study Completion Date
March 26, 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim

4. Oversight

5. Study Description

Brief Summary
This is a 6 week study to investigate the effectiveness and safety of BI 671800 ED in patients with asthma who do not take inhaled corticosteroids.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
389 (Actual)

8. Arms, Groups, and Interventions

Arm Title
BI 671800 (low dose)
Arm Type
Experimental
Arm Description
Patients receive BI 671800 (low dose) capsules twice daily
Arm Title
Fluticasone propionate
Arm Type
Active Comparator
Arm Description
Patients inhale from Fluticasone propionate metered dose inhaler (MDI) twice daily
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Patients receive placebo capsules twice daily
Arm Title
BI 671800 (medium dose)
Arm Type
Experimental
Arm Description
Patients receive BI 671800 (medium dose) capsules twice daily
Arm Title
BI 671800 (high dose)
Arm Type
Experimental
Arm Description
Patients receive BI 671800 (high dose) capsules twice daily
Intervention Type
Drug
Intervention Name(s)
BI 671800
Intervention Description
BI 671800
Intervention Type
Drug
Intervention Name(s)
Fluticasone propionate placebo
Intervention Description
Placebo matching Fluticasone propionate
Intervention Type
Drug
Intervention Name(s)
Fluticasone propionate
Intervention Description
Fluticasone propionate
Intervention Type
Drug
Intervention Name(s)
BI 671800 Placebo
Intervention Description
Placebo matching BI 671800
Primary Outcome Measure Information:
Title
Forced Expiratory Volume in One Second (FEV1) % Predicted Trough Change From Baseline (Mean Observed in the 2 Weeks Prior to Treatment) After Six Weeks of Treatment
Description
Forced expiratory volume in one second (FEV1) % predicted trough change from baseline (mean observed in the 2 weeks prior to treatment) after 6 weeks of treatment, where trough FEV1 % predicted was defined as the mean of the FEV1 % predicted trough values at 25 minutes and 10 minutes prior to dosing on clinic visit. MMRM in the statistical test comments is mixed effects model with repeated measures.
Time Frame
Measurements at baseline (mean observed in the 2 weeks prior to treatment) and at week 6 of treatment.
Secondary Outcome Measure Information:
Title
Asthma Control Questionnaire (ACQ) Mean Score Change From Baseline After Six Weeks of Treatment
Description
Asthma Control Questionnaire (ACQ) mean score change from baseline (mean ACQ score obtained at Week 0) after six weeks of treatment. The Asthma Control Questionnaire (ACQ) is a patient-reported outcome questionnaire containing 7 items. The items are equally weighted and the ACQ score is the mean of the 7 items and therefore between 0 (well controlled) and 6 (extremely poorly controlled) These questions based on recall of the previous 7 days comprise breathlessness, nocturnal waking, symptoms on waking, activity limitation, wheeze, frequency of short-acting beta-adrenergic (SABA) use, and categorized pre-bronchodilator FEV1% predicted.
Time Frame
Measurements at baseline (mean ACQ score obtained at Week 0) and at week 6 of treatment.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Signed informed consent consistent with ICH-GCP Three month history of reversible (12% with 200 mL) asthma (according to GINA) with following spirometry at randomization: FEV1 60%-85%. No ICS previous 3 months prior to screening. Diagnosis of asthma prior to 40 years. ACQ at least 1.5 at randomization. Male or female, 18 to 65 years. Non-smokers or ex-smokers ( less than 10 pack year history) with negative cotinine screen. Able to perform PFT Exclusion criteria: Significant diseases other than asthma or allergic rhinitis. Hepatic transaminases or total bilirubin greater than 1.5 ULN. Hospitalizations for asthma or asthma related intubation within 3 months. Uncontrolled asthma. Respiratory tract infection or exacerbation within 4 weeks. FEV1 less than 40%, more than 12 puffs of SABA on more than two consecutive days or asthma exacerbation during the run-in period. Participation in another interventional study. Pregnant or nursing women. Women of child bearing potential nor using appropriate methods of birth control as defined by protocol
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
1268.17.01043 Boehringer Ingelheim Investigational Site
City
Tucson
State/Province
Arizona
Country
United States
Facility Name
1268.17.01009 Boehringer Ingelheim Investigational Site
City
Cypress
State/Province
California
Country
United States
Facility Name
1268.17.01006 Boehringer Ingelheim Investigational Site
City
Los Angeles
State/Province
California
Country
United States
Facility Name
1268.17.01040 Boehringer Ingelheim Investigational Site
City
Palmdale
State/Province
California
Country
United States
Facility Name
1268.17.01024 Boehringer Ingelheim Investigational Site
City
San Jose
State/Province
California
Country
United States
Facility Name
1268.17.01003 Boehringer Ingelheim Investigational Site
City
Stockton
State/Province
California
Country
United States
Facility Name
1268.17.01015 Boehringer Ingelheim Investigational Site
City
Colorado Springs
State/Province
Colorado
Country
United States
Facility Name
1268.17.01001 Boehringer Ingelheim Investigational Site
City
Denver
State/Province
Colorado
Country
United States
Facility Name
1268.17.01016 Boehringer Ingelheim Investigational Site
City
Lakewood
State/Province
Colorado
Country
United States
Facility Name
1268.17.01033 Boehringer Ingelheim Investigational Site
City
Wheat Ridge
State/Province
Colorado
Country
United States
Facility Name
1268.17.01045 Boehringer Ingelheim Investigational Site
City
DeLand
State/Province
Florida
Country
United States
Facility Name
1268.17.01036 Boehringer Ingelheim Investigational Site
City
Normal
State/Province
Illinois
Country
United States
Facility Name
1268.17.01025 Boehringer Ingelheim Investigational Site
City
South Bend
State/Province
Indiana
Country
United States
Facility Name
1268.17.01005 Boehringer Ingelheim Investigational Site
City
Iowa City
State/Province
Iowa
Country
United States
Facility Name
1268.17.01034 Boehringer Ingelheim Investigational Site
City
Baltimore
State/Province
Maryland
Country
United States
Facility Name
1268.17.01014 Boehringer Ingelheim Investigational Site
City
North Dartmouth
State/Province
Massachusetts
Country
United States
Facility Name
1268.17.01030 Boehringer Ingelheim Investigational Site
City
North Dartmouth
State/Province
Massachusetts
Country
United States
Facility Name
1268.17.01027 Boehringer Ingelheim Investigational Site
City
Novi
State/Province
Michigan
Country
United States
Facility Name
1268.17.01032 Boehringer Ingelheim Investigational Site
City
Minneapolis
State/Province
Minnesota
Country
United States
Facility Name
1268.17.01010 Boehringer Ingelheim Investigational Site
City
Saint Louis
State/Province
Missouri
Country
United States
Facility Name
1268.17.01037 Boehringer Ingelheim Investigational Site
City
Saint Louis
State/Province
Missouri
Country
United States
Facility Name
1268.17.01022 Boehringer Ingelheim Investigational Site
City
Bozeman
State/Province
Montana
Country
United States
Facility Name
1268.17.01008 Boehringer Ingelheim Investigational Site
City
Bellevue
State/Province
Nebraska
Country
United States
Facility Name
1268.17.01011 Boehringer Ingelheim Investigational Site
City
Raleigh
State/Province
North Carolina
Country
United States
Facility Name
1268.17.01004 Boehringer Ingelheim Investigational Site
City
Cincinnati
State/Province
Ohio
Country
United States
Facility Name
1268.17.01038 Boehringer Ingelheim Investigational Site
City
Oklahoma City
State/Province
Oklahoma
Country
United States
Facility Name
1268.17.01042 Boehringer Ingelheim Investigational Site
City
Philadelphia
State/Province
Pennsylvania
Country
United States
Facility Name
1268.17.01007 Boehringer Ingelheim Investigational Site
City
Charleston
State/Province
South Carolina
Country
United States
Facility Name
1268.17.01031 Boehringer Ingelheim Investigational Site
City
Easley
State/Province
South Carolina
Country
United States
Facility Name
1268.17.01039 Boehringer Ingelheim Investigational Site
City
Fort Mill
State/Province
South Carolina
Country
United States
Facility Name
1268.17.01026 Boehringer Ingelheim Investigational Site
City
Greenville
State/Province
South Carolina
Country
United States
Facility Name
1268.17.01029 Boehringer Ingelheim Investigational Site
City
Greenville
State/Province
South Carolina
Country
United States
Facility Name
1268.17.01049 Boehringer Ingelheim Investigational Site
City
Spartanburg
State/Province
South Carolina
Country
United States
Facility Name
1268.17.01019 Boehringer Ingelheim Investigational Site
City
Dallas
State/Province
Texas
Country
United States
Facility Name
1268.17.01012 Boehringer Ingelheim Investigational Site
City
El Paso
State/Province
Texas
Country
United States
Facility Name
1268.17.01023 Boehringer Ingelheim Investigational Site
City
Houston
State/Province
Texas
Country
United States
Facility Name
1268.17.01048 Boehringer Ingelheim Investigational Site
City
Killeen
State/Province
Texas
Country
United States
Facility Name
1268.17.01028 Boehringer Ingelheim Investigational Site
City
New Braunfels
State/Province
Texas
Country
United States
Facility Name
1268.17.01035 Boehringer Ingelheim Investigational Site
City
San Antonio
State/Province
Texas
Country
United States
Facility Name
1268.17.01047 Boehringer Ingelheim Investigational Site
City
Tacoma
State/Province
Washington
Country
United States
Facility Name
1268.17.61001 Boehringer Ingelheim Investigational Site
City
Adelaide
State/Province
South Australia
Country
Australia
Facility Name
1268.17.02012 Boehringer Ingelheim Investigational Site
City
Hawkesbury
State/Province
Ontario
Country
Canada
Facility Name
1268.17.02010 Boehringer Ingelheim Investigational Site
City
Mississauga
State/Province
Ontario
Country
Canada
Facility Name
1268.17.02014 Boehringer Ingelheim Investigational Site
City
Newmarket
State/Province
Ontario
Country
Canada
Facility Name
1268.17.02015 Boehringer Ingelheim Investigational Site
City
Sudbury
State/Province
Ontario
Country
Canada
Facility Name
1268.17.02003 Boehringer Ingelheim Investigational Site
City
Toronto
State/Province
Ontario
Country
Canada
Facility Name
1268.17.02013 Boehringer Ingelheim Investigational Site
City
Toronto
State/Province
Ontario
Country
Canada
Facility Name
1268.17.02001 Boehringer Ingelheim Investigational Site
City
Quebec
Country
Canada
Facility Name
1268.17.02004 Boehringer Ingelheim Investigational Site
City
Quebec
Country
Canada
Facility Name
1268.17.57003 Boehringer Ingelheim Investigational Site
City
Bogotá
Country
Colombia
Facility Name
1268.17.57004 Boehringer Ingelheim Investigational Site
City
Bogotá
Country
Colombia
Facility Name
1268.17.57002 Boehringer Ingelheim Investigational Site
City
Medellín
Country
Colombia
Facility Name
1268.17.82007 Boehringer Ingelheim Investigational Site
City
Cheongju
Country
Korea, Republic of
Facility Name
1268.17.82001 Boehringer Ingelheim Investigational Site
City
Seoul
Country
Korea, Republic of
Facility Name
1268.17.82002 Boehringer Ingelheim Investigational Site
City
Seoul
Country
Korea, Republic of
Facility Name
1268.17.82004 Boehringer Ingelheim Investigational Site
City
Seoul
Country
Korea, Republic of
Facility Name
1268.17.82005 Boehringer Ingelheim Investigational Site
City
Seoul
Country
Korea, Republic of
Facility Name
1268.17.82006 Boehringer Ingelheim Investigational Site
City
Seoul
Country
Korea, Republic of
Facility Name
1268.17.82003 Boehringer Ingelheim Investigational Site
City
Suwon
Country
Korea, Republic of
Facility Name
1268.17.82008 Boehringer Ingelheim Investigational Site
City
Wonju
Country
Korea, Republic of
Facility Name
1268.17.52002 Boehringer Ingelheim Investigational Site
City
Cuernavaca
Country
Mexico
Facility Name
1268.17.52001 Boehringer Ingelheim Investigational Site
City
Monterrey
Country
Mexico
Facility Name
1268.17.52004 Boehringer Ingelheim Investigational Site
City
Toriello Guerra
Country
Mexico
Facility Name
1268.17.52003 Boehringer Ingelheim Investigational Site
City
Zona Río
Country
Mexico
Facility Name
1268.17.64001 Boehringer Ingelheim Investigational Site
City
Christchurch
Country
New Zealand
Facility Name
1268.17.64003 Boehringer Ingelheim Investigational Site
City
Greenlane East Auckland
Country
New Zealand
Facility Name
1268.17.64002 Boehringer Ingelheim Investigational Site
City
Newtown Wellington NZ
Country
New Zealand
Facility Name
1268.17.51003 Boehringer Ingelheim Investigational Site
City
Jesús María
Country
Peru
Facility Name
1268.17.51002 Boehringer Ingelheim Investigational Site
City
Lima
Country
Peru
Facility Name
1268.17.51006 Boehringer Ingelheim Investigational Site
City
San Borja
Country
Peru
Facility Name
1268.17.51004 Boehringer Ingelheim Investigational Site
City
San Isidro.
Country
Peru
Facility Name
1268.17.51005 Boehringer Ingelheim Investigational Site
City
Santiago de Surco
Country
Peru
Facility Name
1268.17.51001 Boehringer Ingelheim Investigational Site
City
Urb. Ingeniería
Country
Peru
Facility Name
1268.17.63007 Boehringer Ingelheim Investigational Site
City
Caloocan City
Country
Philippines
Facility Name
1268.17.63002 Boehringer Ingelheim Investigational Site
City
Manila
Country
Philippines
Facility Name
1268.17.63001 Boehringer Ingelheim Investigational Site
City
Quezon City
Country
Philippines
Facility Name
1268.17.63003 Boehringer Ingelheim Investigational Site
City
Quezon City
Country
Philippines
Facility Name
1268.17.63004 Boehringer Ingelheim Investigational Site
City
Quezon City
Country
Philippines
Facility Name
1268.17.63005 Boehringer Ingelheim Investigational Site
City
Quezon City
Country
Philippines
Facility Name
1268.17.63006 Boehringer Ingelheim Investigational Site
City
Quezon City
Country
Philippines
Facility Name
1268.17.86210 Boehringer Ingelheim Investigational Site
City
Chiayi City
Country
Taiwan
Facility Name
1268.17.86211 Boehringer Ingelheim Investigational Site
City
Kaohsiung City
Country
Taiwan
Facility Name
1268.17.86207 Boehringer Ingelheim Investigational Site
City
Taichung
Country
Taiwan
Facility Name
1268.17.86208 Boehringer Ingelheim Investigational Site
City
Taichung
Country
Taiwan
Facility Name
1268.17.86209 Boehringer Ingelheim Investigational Site
City
Taichung
Country
Taiwan
Facility Name
1268.17.86201 Boehringer Ingelheim Investigational Site
City
Taipei
Country
Taiwan
Facility Name
1268.17.86202 Boehringer Ingelheim Investigational Site
City
Taipei
Country
Taiwan
Facility Name
1268.17.86203 Boehringer Ingelheim Investigational Site
City
Taipei
Country
Taiwan
Facility Name
1268.17.86204 Boehringer Ingelheim Investigational Site
City
Taipei
Country
Taiwan
Facility Name
1268.17.86205 Boehringer Ingelheim Investigational Site
City
Taipei
Country
Taiwan
Facility Name
1268.17.86206 Boehringer Ingelheim Investigational Site
City
Taipei
Country
Taiwan
Facility Name
1268.17.86200 Boehringer Ingelheim Investigational Site
City
Taoyuan County
Country
Taiwan

12. IPD Sharing Statement

Links:
URL
http://www.mystudywindow.com/
Description
Related Info

Learn more about this trial

BI 671800 ED in Steroid-naive Asthmatic Patients

We'll reach out to this number within 24 hrs